Allergy Therapeutics approved to conduct trials of its allergy vaccine in Japan

By Lisa Kerner

Charlotte, N.C., July 19 - Allergy Therapeutics plc said the Pharmaceutical and Medical Devices Agency in Japan has accepted the company's plans to conduct additional trials of its ultra short-course vaccine Pollinex Quattro Grass.

The agency reviewed preclinical, manufacturing and clinical data for the grass pollen product.

Allergy Therapeutics will begin the clinical trials once it finds a suitable partner in Japan for its Grass and Japanese Cedar development projects, according to a company news release.

"Twenty-nine million people in Japan suffer from allergic rhinitis, a significant portion because of pollinosis," chief executive officer Keith Carter said in the release.

"There are currently no equivalent products available to treat the cause of this allergy. These facts, combined with aggressive public health awareness campaigns, contrive to provide a sizable and readily accessible marketplace."

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination located in West Sussex, U.K.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.